Pentoxifylline therapy

• US 5,532,003 A
• Filed: 01/18/1994
• Issued: 07/02/1996
• Est. Priority Date: 01/18/1994
• Status: Expired due to Term

• Current Assignee: ALZA Corporation (Johnson & Johnson)
• Original Assignee: ALZA Corporation (Johnson & Johnson)
• Inventors: Wong, Patrick S.-L., Ayer, Atul D., Guittard, George V.
• Primary Examiner(s): BROUILLETTE, D GABRIELLE
• Application Number:
  US08/183,007
• Time in Patent Office: 896 Days
• Field of Search: 424/473, 424/413, 424/482, 424/489
• US Class Current: 424/473
• CPC Class Codes: A61K 31/52 Purines, e.g. adenine
• CPC Class Codes: A61K 9/0004 Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
• CPC Class Codes: A61K 9/2031 obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
• CPC Class Codes: A61K 9/2054 Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Abstract

A dosage form is disclosed for delivering pentoxifylline to a patient in need of pentoxifylline therapy. A method is discussed for delivery pentoxifylline to a patient at a dosage form controlled rate over an extended period of time.

Claims

1. A pharmaceutical granular composition comprising 20 wt % to 85 wt % of pentoxifylline, 5 wt % to 35 wt % of a polyethylene oxide possessing a 175,000 to 225,000 molecular weight, 0 wt % to 40 wt % of a hydroxypropylalkylcellulose possessing a 9,200 to 240,000 molecular weight, and 0 wt % to 15 wt % of a hydroxyalkylcellulose possessing a 7,200 to 650,000 molecular weight, which pharmaceutical granular composition in dosage form is indicated for the continuous-release of pentoxifylline to a patient over an extended time up to 24 hours.

2. A pharmaceutical composition comprising granules of 20 wt % to 85 wt % of pentoxifylline, 5 wt % to 75 wt % of a polyethylene oxide possessing a 175,000 to 325,000 molecular weight, 0 wt % to 40 wt % of a hydroxypropylalkylcellulose possessing a 9,200 to 240,000 molecular weight, a 0 wt % to 15 wt % of a hydroxyalklcellulose possessing a 7,200 to 650,000 molecular weight 0 wt % to 20 wt % polyvinyl pyrrolidone 20,000 to 50,000 molecular weight, which pharmaceutical composition comprising the granules is indicated for the continuous-release of pentoxifylline to a patient over an extended time up to 24 hours.